Get started
Author

Cristina P. Rodriguez

Observed names: C. P. Rodriguez, C. Rodriguez, C.P. Rodriguez, Cristina P. Rodriguez, Cristina P Rodriguez, Cristina Rodriguez
Observed institutions: Cleveland Clinic, Seattle Cancer Care Alliance, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, University of Washington, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Washington Medical Center, Henry Ford Hospital, Moffitt Cancer Center, University of Alabama at Birmingham, Massachusetts General Hospital, Fred Hutch Cancer Center, Dana-Farber Brigham Cancer Center, Duke Cancer Institute
ORCID: 0000-0003-3568-2630
Observed ORCID: 0000-0003-3568-2630
OpenAlex ID: A5101636839
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
2022 · Jimmy J. Caudell, Maura L. Gillison, et al. · Journal of the National Comprehensive Cancer Network · 528
Management of Salivary Gland Malignancy: ASCO Guideline
2021 · Jessica L. Geiger, Nofisat Ismaila, et al. · Journal of Clinical Oncology · 444
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
2025 · Ravindra Uppaluri, Robert I. Haddad, et al. · New England Journal of Medicine · 429
Head and Neck Cancers, Version 2.2014
2014 · David G. Pfister, Sharon Spencer, et al. · Journal of the National Comprehensive Cancer Network · 283
PDF
Head and Neck Cancers, Version 1.2015
2015 · David G. Pfister, Sharon Spencer, et al. · Journal of the National Comprehensive Cancer Network · 262
PDF
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
2025 · A. Dimitrios Colevas, Anthony J. Cmelak, et al. · Journal of the National Comprehensive Cancer Network · 200
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
2019 · Cristina P. Rodriguez, Qian (Vicky) Wu, et al. · Clinical Cancer Research · 180
A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
2018 · Eduardo Méndez, Cristina P. Rodriguez, et al. · Clinical Cancer Research · 107
A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer
2010 · Cristina P. Rodriguez, David J. Adelstein, et al. · Journal of Thoracic Oncology · 56
Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction
2009 · David J. Adelstein, Thomas W. Rice, et al. · Journal of Thoracic Oncology · 52
PDF
The mutational landscape of recurrent versus nonrecurrent human papillomavirus–related oropharyngeal cancer
2018 · R. Alex Harbison, Mark Kubik, et al. · JCI Insight · 51
PDF
Radiotherapy with Durvalumab vs. Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer and a Contraindication to Cisplatin: Phase II Results of NRG-HN004
2022 · L.K. Mell, P. Torres-Saavedra, et al. · International Journal of Radiation Oncology*Biology*Physics · 50
FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition
2020 · Ahmed Diab, Hakan Gem, et al. · Proceedings of the National Academy of Sciences · 33
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
2007 · Rachid Baz, Cristina Rodriguez, et al. · Cancer · 32
PDF
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma
2014 · L.M. Krug, A.J. Wozniak, et al. · Lung Cancer · 31
Performance status ( PS ) as a predictor of poor response to immune checkpoint inhibitors ( ICI ) in recurrent/metastatic head and neck cancer ( RMHNSCC ) patients
2022 · Cameron Chalker, Jenna M. Voutsinas, et al. · Cancer Medicine · 26
What is new in the management of salivary gland cancers?
2011 · David J Adelstein, Cristina P Rodriguez · Current Opinion in Oncology · 23
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).
2024 · Alexander Dimitrios Colevas, Christine H. Chung, et al. · Journal of Clinical Oncology · 21
PDF
919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
2020 · R. Ferrarotto, L.J. Wirth, et al. · Annals of Oncology · 19
Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies
2017 · Cristina P. Rodriguez, Renato G. Martins, et al. · Head & Neck · 19
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
2023 · Aditi Shastri, Eric J Feldman, et al. · Blood · 18
Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
2024 · Tatyana Feldman, Enrica Marchi, et al. · Blood · 15
PDF
The role of elective neck dissection in high‐grade parotid malignancy: A hospital‐based cohort study
2019 · R. Alex Harbison, Alan J. Gray, et al. · The Laryngoscope · 14
Racial disparity in oncologic and quality‐of‐life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial
2018 · Margaret K. Guerriero, Mary W. Redman, et al. · Cancer · 13
PDF
Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC).
2018 · Cristina P. Rodriguez, Vicky Wu, et al. · Journal of Clinical Oncology · 11
Works count: 104
Citation count: 3,066
H-index: 19
I10-index: 31
Year
Topic
Type